Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Theresa Carioti
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0002-8082-8187
Observed ORCID:
0000-0002-8082-8187
OpenAlex ID:
A5035275363
FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.
2018
·
Aviva C Krauss
, Flora Mulkey
, et al.
·
Journal of Clinical Oncology
·
20
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective
2023
·
Andrea C. Baines
, Maryam Sarraf Yazdy
, et al.
·
Clinical Cancer Research
·
14
PDF
Autopsy of a Drug Withdrawal — The Case of Melphalan Flufenamide
2024
·
Bindu Kanapuru
, Theresa Carioti
, et al.
·
New England Journal of Medicine
·
6
FDA Analysis of Survival Outcomes in Older Adults with Relapsed-Refractory Multiple Myeloma (RRMM) Treated with Novel Drug Regimens
2019
·
Bindu Kanapuru
, Susan Jin
, et al.
·
Blood
·
2
FDA Analysis of Outcomes in Older Adults with Relapsed or Refractory Multiple Myeloma
2018
·
Bindu Kanapuru
, Susan Jin
, et al.
·
Blood
·
1
FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
2026
·
Rachel Ershler
, Xueping Zhou
, et al.
·
Clinical Cancer Research
PDF
Bridging the gap: FDA diversity-related postmarketing requirements.
2023
·
Natasha L. Kormanik
, Theresa Carioti
, et al.
·
Journal of Clinical Oncology
Minimal Residual Disease (MRD) Data in Hematologic Malignancy Drug Applications and Prescribing Information: FDA Analysis
2021
·
Maryam Sarraf Yazdy
, Andrea C. Baines
, et al.
·
Blood
Show more works
View as search
Works count:
8
Citation count:
43
H-index:
3
I10-index:
2
Year
Topic
Type